AI-generated summary
The authors report a randomized, double-blind, placebo-controlled trial of home-administered transcranial photobiomodulation in 80 people with mild cognitive impairment due to Alzheimer's disease over 12 weeks. Active treatment was associated with greater improvement on the MoCA-K score than placebo, with no device-related adverse events reported.
- Participants
- 80
- Who or what was studied
- Adults with mild cognitive impairment due to Alzheimer's disease meeting NIA-AA criteria
- Wavelengths
- 808 nm
- Limits stated in the abstract
- The abstract does not report a sample size per group or long-term follow-up, and the authors' mechanistic explanations are interpretive rather than directly measured.
Written by an AI model from this paper’s abstract only and checked automatically against it, but it can still be wrong. It is not medical advice. Read the full paper. See the editorial policy.
Abstract
The full abstract is not shown here because it is protected by the publisher’s copyright. Read it on journals.sagepub.com.
Record from PubMed, a service of the National Library of Medicine.
Light parameters mentioned
Found in the title and abstract by pattern. They may be incomplete, so check the paper before comparing studies.
- Wavelength
- 808 nm
How to read a trial: what to check before relying on this kind of research.
Terms in this paper: Transcranial photobiomodulation, Mild cognitive impairment, Photobiomodulation, Placebo-controlled, Montreal Cognitive Assessment, Near-infrared, Neuromodulation, Primary outcome. Each links to its definition in the glossary.
A summary of published research, not medical advice. One study rarely settles a question. See the disclaimer and how to read research.